Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (NYSE: ABBV) is a pharmaceutical preparation manufacturing company that regularly issues news on its medicines, research programs, collaborations and manufacturing plans. Company communications emphasize a mission to discover and deliver medicines and solutions in key therapeutic areas such as immunology, oncology, neuroscience and eye care, as well as offerings in its Allergan Aesthetics portfolio.
News about AbbVie often covers clinical and scientific developments, particularly in oncology and blood cancers. The company has reported new data at major medical meetings, including results for investigational agents like etentamig (ABBV‑383) and PVEK, and updates on approved medicines such as EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax). Releases may detail trial outcomes, regulatory milestones, and additional indications under investigation.
Investors and observers can also find corporate and financial updates in AbbVie’s news flow, including announcements of earnings conference calls, participation in healthcare and investor conferences, and guidance-related information that aligns with its SEC filings. The company additionally highlights strategic agreements and collaborations, such as its exclusive licensing agreement with RemeGen for the PD‑1/VEGF bispecific antibody RC148 and its voluntary agreement with the U.S. administration focused on access, affordability and U.S.-based investment.
Another recurring theme in AbbVie’s news is manufacturing and investment activity. The company has announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, to expand drug delivery device manufacturing for immunology and neuroscience medicines, and has referenced multi‑year commitments to U.S. R&D and capital investments. AbbVie also publishes stories on patient- and community-focused initiatives, such as the “Second Winds” film about people living with chronic lymphocytic leukemia. For readers tracking ABBV, this news stream provides insight into the company’s research pipeline, regulatory progress, capital allocation and patient engagement efforts.
AbbVie (NYSE:ABBV) announced that the FDA has accepted for review the supplemental premarket approval (sPMA) application for SKINVIVE by JUVÉDERM® to reduce neck lines and improve neck appearance. The product is currently approved in the U.S. for improving cheek skin smoothness in adults over 21.
The application is supported by a successful clinical study where 80% of patients achieved at least a 1-grade improvement in horizontal neck lines at month 1, and nearly 90% reported improvement in neck appearance. Treatment-emergent adverse events were mild and consistent with the known safety profile.
If approved, SKINVIVE by JUVÉDERM® would become the first hyaluronic acid injectable treatment specifically targeting neck lines, addressing a significant market need as neck appearance is a top concern among aesthetic treatment seekers.
AbbVie (NYSE: ABBV) has scheduled its second-quarter 2025 financial results announcement for Thursday, July 31, 2025, before market opening. The company will host a live earnings conference call at 8 a.m. Central time. Investors can access the webcast through AbbVie's Investor Relations website at investors.abbvie.com, with an archived version available later that day.